Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.

BACKGROUND: Licensed ranibizumab (0.5 mg/0.05 ml Lucentis®; Novartis International AG, Basel, Switzerland) and aflibercept (2 mg/0.05 ml Eylea®; Bayer AG, Leverkusen, Germany) and unlicensed bevacizumab (1.25 mg/0.05 ml Avastin®; F. Hoffmann-La Roche AG, Basel, Switzerland) are used to treat macula...

全面介紹

Na minha lista:
書目詳細資料
發表在:Health Technol Assess
Main Authors: Hykin, Philip, Prevost, A Toby, Sivaprasad, Sobha, Vasconcelos, Joana C, Murphy, Caroline, Kelly, Joanna, Ramu, Jayashree, Alshreef, Abualbishr, Flight, Laura, Pennington, Rebekah, Hounsome, Barry, Lever, Ellen, Metry, Andrew, Poku, Edith, Yang, Yit, Harding, Simon P, Lotery, Andrew, Chakravarthy, Usha, Brazier, John
格式: Artigo
語言:Inglês
出版: NIHR Journals Library 2021
主題:
Research Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC8287375/
https://ncbi.nlm.nih.gov/pubmed/34132192
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3310/hta25380
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍